Top

Published in:

Open Access 01-09-2020 | Metastasis | Non-Thematic Review

Solute transporters and malignancy: establishing the role of uptake transporters in breast cancer and breast cancer metastasis

Authors: Rachel Sutherland, Annette Meeson, Simon Lowes

Published in: Cancer and Metastasis Reviews | Issue 3/2020

Abstract

The solute carrier (SLC) superfamily encompasses a large variety of membrane-bound transporters required to transport a diverse array of substrates over biological membranes. Physiologically, they are essential for nutrient uptake, ion transport and waste removal. However, accumulating evidence suggest that up- and/or downregulation of SLCs may play a pivotal role in the pathogenesis of human malignancy. Endogenous substrates of SLCs include oestrogen and its conjugates, the handling of which may be of importance in hormone-dependent cancers. The SLCs play a significant role in the handling of therapeutic agents including anticancer drugs. Differential SLC expression in cancers may, therefore, impact on the efficacy of treatments. However, there is also a small body of evidence to suggest the dysregulated expression of some of these transporters may be linked to cancer metastasis. This review draws on the current knowledge of the roles of SLC transporters in human cancers in order to highlight the potential significance of these solute carriers in breast cancer pathogenesis and treatment.

Choi, Y. H., & Yu, A.-M. (2014). ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Current Pharmaceutical Design, 20(5), 793–807.PubMedPubMedCentral

Hediger, M. A., Clémençon, B., Burrier, R. E., & Bruford, E. A. (2013). The ABCs of membrane transporters in health and disease (SLC series): Introduction. Molecular aspects of medicine., 34(2–3), 95–107.PubMedPubMedCentral

Li, Q., & Shu, Y. (2014). Role of solute carriers in response to anticancer drugs. Molecular and cellular therapies, 2, 15.PubMedPubMedCentral

Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015). SLC transporters as therapeutic targets: Emerging opportunities. Nature reviews Drug discovery., 14(8), 543–560.PubMedPubMedCentral

Roth, M., Obaidat, A., & Hagenbuch, B. (2012). OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. British journal of pharmacology., 165(5), 1260–1287.PubMedPubMedCentral

Hagenbuch, B., & Stieger, B. (2013). The SLCO (former SLC21) superfamily of transporters. Molecular Aspects of Medicine., 34(2), 396–412.PubMedPubMedCentral

Stieger, B., & Hagenbuch, B. (2014). Organic anion-transporting polypeptides. Current topics in membranes., 73, 205–232.PubMedPubMedCentral

Thakkar, N., Lockhart, A. C., & Lee, W. (2015). Role of organic anion-transporting polypeptides (OATPs) in cancer therapy. The AAPS journal., 17(3), 535–545.PubMedPubMedCentral

Anzai, N., Kanai, Y., & Endou, H. (2006). Organic anion transporter family: current knowledge. Journal of Pharmacological Sciences, 100(5), 411–426.PubMed

10.

Koepsell, H. (2013). The SLC22 family with transporters of organic cations, anions and zwitterions. Molecular Aspects of Medicine., 34(2), 413–435.PubMed

11.

Nakanishi, T., & Tamai, I. (2011). Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. Journal of Pharmaceutical Sciences, 100(9), 3731–3750.PubMed

12.

Nigam, S. K., Bush, K. T., Martovetsky, G., Ahn, S.-Y., Liu, H. C., Richard, E., Bhatnagar, V., & Wu, W. (2015). The organic anion transporter (OAT) family: A systems biology perspective. Physiological Reviews, 95(1), 83–123.PubMedPubMedCentral

13.

Volk, C. (2014). OCTs, OATs, and OCTNs: structure and function of the polyspecific organic ion transporters of the SLC22 family. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling., 3(1), 1–13.

14.

Obaidat, A., Roth, M., & Hagenbuch, B. (2012). The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annual review of pharmacology and toxicology., 52, 135–151.PubMed

15.

Arakawa, H., Nakanishi, T., Yanagihara, C., Nishimoto, T., Wakayama, T., Mizokami, A., Namiki, M., Kawai, K., & Tamai, I. (2012). Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions. Biochemical Pharmacology, 84(8), 1070–1077.PubMed

16.

Ballestero, M. R., Monte, M. J., Briz, O., Jimenez, F., Gonzalez-San Martin, F., & Marin, J. J. (2006). Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochemical Pharmacology, 72(6), 729–738.PubMed

17.

Bronger, H., Konig, J., Kopplow, K., Steiner, H. H., Ahmadi, R., Herold-Mende, C., et al. (2005). ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Research, 65(24), 11419–11428.PubMed

18.

Kounnis, V., Ioachim, E., Svoboda, M., Tzakos, A., Sainis, I., Thalhammer, T., et al. (2011). Expression of organic anion-transporting polypeptides 1B3, 1B1, and 1A2 in human pancreatic cancer reveals a new class of potential therapeutic targets. OncoTargets and therapy., 4, 27–32.PubMedPubMedCentral

19.

Liedauer, R., Svoboda, M., Wlcek, K., Arrich, F., Ja, W., Toma, C., et al. (2009). Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts. Oncology reports., 22(6), 1485–1492.PubMed

20.

Miki, Y., Suzuki, T., Kitada, K., Yabuki, N., Shibuya, R., Moriya, T., Ishida, T., Ohuchi, N., Blumberg, B., & Sasano, H. (2006). Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Research, 66(1), 535–542.PubMed

21.

Zolk, O., Schnepf, R., Muschler, M., Fromm, M. F., Wendler, O., Traxdorf, M., Iro, H., & Zenk, J. (2013). Transporter gene expression in human head and neck squamous cell carcinoma and associated epigenetic regulatory mechanisms. The American journal of pathology., 182(1), 234–243.PubMed

22.

Meyer zu Schwabedissen, H. E., Tirona, R. G., Yip, C. S., Ho, R. H., & Kim, R. B. (2008). Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Research., 68(22), 9338–9347.PubMedPubMedCentral

23.

Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, Tong D, et al. Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2011;65(6):417–26.

24.

Wright, J. L., Kwon, E. M., Ostrander, E. A., Montgomery, R. B., Lin, D. W., Vessella, R., Stanford, J. L., & Mostaghel, E. A. (2011). Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology., 20(4), 619–627.

25.

Hamada, A., Sissung, T., Price, D. K., Danesi, R., Chau, C. H., Sharifi, N., Venzon, D., Maeda, K., Nagao, K., Sparreboom, A., Mitsuya, H., Dahut, W. L., & Figg, W. D. (2008). Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research., 14(11), 3312–3318.

26.

Lee, W., Belkhiri, A., Lockhart, A. C., Merchant, N., Glaeser, H., Harris, E. I., Washington, M. K., Brunt, E. M., Zaika, A., Kim, R. B., & el-Rifai, W. (2008). Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Research, 68(24), 10315–10323.PubMedPubMedCentral

27.

Monks, N. R., Liu, S., Xu, Y., Yu, H., Bendelow, A. S., & Moscow, J. A. (2007). Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells. Molecular Cancer Therapeutics, 6(2), 587–598.PubMed

28.

Muto, M., Onogawa, T., Suzuki, T., Ishida, T., Rikiyama, T., Katayose, Y., Ohuchi, N., Sasano, H., Abe, T., & Unno, M. (2007). Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer science., 98(10), 1570–1576.PubMed

29.

Pressler, H., Sissung, T. M., Venzon, D., Price, D. K., & Figg, W. D. (2011). Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One, 6(5), e20372.PubMedPubMedCentral

30.

Svoboda, M., Riha, J., Wlcek, K., Jaeger, W., & Thalhammer, T. (2011). Organic anion transporting polypeptides (OATPs): regulation of expression and function. Current drug metabolism., 12(2), 139–153.PubMed

31.

Thakkar, N., Kim, K., Jang, E. R., Han, S., Kim, K., Kim, D., Merchant, N., Lockhart, A. C., & Lee, W. (2013). A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Molecular Pharmaceutics, 10(1), 406–416.PubMed

32.

Hays, A., Apte, U., & Hagenbuch, B. (2013). Organic anion transporting polypeptides expressed in pancreatic cancer may serve as potential diagnostic markers and therapeutic targets for early stage adenocarcinomas. Pharmaceutical Research, 30(9), 2260–2269.PubMedPubMedCentral

33.

Cui, Y., Konig, J., Nies, A. T., Pfannschmidt, M., Hergt, M., Franke, W. W., et al. (2003). Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Laboratory investigation; a journal of technical methods and pathology, 83(4), 527–538.PubMed

34.

Kinoshita, M., & Miyata, M. (2002). Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci. Hepatology., 36(2), 433–438.PubMed

35.

Vavricka, S. R., Jung, D., Fried, M., Grützner, U., Meier, P. J., & Kullak-Ublick, G. A. (2004). The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3β in hepatocellular carcinoma. Journal of Hepatology., 40(2), 212–218.PubMed

36.

Zollner, G., Wagner, M., Fickert, P., Silbert, D., Fuchsbichler, A., Zatloukal, K., Denk, H., & Trauner, M. (2005). Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver international : official journal of the International Association for the Study of the Liver., 25(2), 367–379.

37.

Nagai, M., Furihata, T., Matsumoto, S., Ishii, S., Motohashi, S., Yoshino, I., Ugajin, M., Miyajima, A., Matsumoto, S., & Chiba, K. (2012). Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochemical and biophysical research communications., 418(4), 818–823.PubMed

38.

Kindla, J., Rau, T. T., Jung, R., Fasching, P. A., Strick, R., Stoehr, R., Hartmann, A., Fromm, M. F., & König, J. (2011). Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue. Cancer biology & therapy., 11(6), 584–591.

39.

Bleasby, K., Castle, J. C., Roberts, C. J., Cheng, C., Bailey, W. J., Sina, J. F., Kulkarni, A. V., Hafey, M. J., Evers, R., Johnson, J. M., Ulrich, R. G., & Slatter, J. G. (2006). Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica., 36(10–11), 963–988.PubMed

40.

Banerjee, N., Allen, C., & Bendayan, R. (2012). Differential role of organic anion-transporting polypeptides in estrone-3-Sulphate uptake by breast epithelial cells and breast cancer cells. Journal of Pharmacology and Experimental Therapeutics., 342(2), 510–519.PubMed

41.

Maeda, T., Irokawa, M., Arakawa, H., Kuraoka, E., Nozawa, T., Tateoka, R., Itoh, Y., Nakanishi, T., & Tamai, I. (2010). Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. The Journal of steroid biochemistry and molecular biology., 122(4), 180–185.PubMed

42.

Iusuf, D., Hendrikx, J. J., van Esch, A., van de Steeg, E., Wagenaar, E., Rosing, H., et al. (2015). Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel. International journal of cancer., 136(1), 225–233.

43.

Leonhardt, M., Keiser, M., Oswald, S., Kühn, J., Jia, J., Grube, M., Kroemer, H. K., Siegmund, W., & Weitschies, W. (2010). Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: Role of human organic anion transporters. Drug Metabolism and Disposition., 38(7), 1024–1028.PubMed

44.

van de Steeg, E., van Esch, A., Wagenaar, E., Kenworthy, K. E., & Schinkel, A. H. (2013). Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clinical cancer research : an official journal of the American Association for Cancer Research., 19(4), 821–832.

45.

Pizzagalli, F., Hagenbuch, B., Stieger, B., Klenk, U., Folkers, G., & Meier, P. J. (2002). Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Molecular endocrinology (Baltimore, Md), 16(10), 2283–2296.

46.

Hagenbuch, B. (2007). Cellular entry of thyroid hormones by organic anion transporting polypeptides. Best Practice & Research Clinical Endocrinology & Metabolism., 21(2), 209–221.

47.

Holla VR, Backlund MG, Yang P, Newman RA, DuBois RN. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer prevention research (Philadelphia, Pa). 2008;](2):93–99.

48.

Wlcek, K., Svoboda, M., Riha, J., Zakaria, S., Olszewski, U., Dvorak, Z., Sellner, F., Ellinger, I., Jäger, W., & Thalhammer, T. (2011). The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer. Cancer biology & therapy., 11(9), 801–811.

49.

Wlcek, K., Svoboda, M., Thalhammer, T., Sellner, F., Krupitza, G., & Jaeger, W. (2008). Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer biology & therapy., 7(9), 1450–1455.

50.

Kochel, T. J., Goloubeva, O. G., & Fulton, A. M. (2016). Upregulation of cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) pathway member multiple drug resistance-associated protein 4 (MRP4) and downregulation of prostaglandin transporter (PGT) and 15-prostaglandin dehydrogenase (15-PGDH) in triple-negative breast cancer. Breast cancer : basic and clinical research., 10, 61–70.

51.

Nozawa, T., Imai, K., Nezu, J., Tsuji, A., & Tamai, I. (2004). Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. The Journal of pharmacology and experimental therapeutics., 308(2), 438–445.PubMed

52.

Al Sarakbi, W., Mokbel, R., Salhab, M., Jiang, W. G., Reed, M. J., & Mokbel, K. (2006). The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer. Anticancer Research, 26(6c), 4985–4990.PubMed

53.

Pizzagalli, F., Varga, Z., Huber, R. D., Folkers, G., Meier, P. J., & St-Pierre, M. V. (2003). Identification of steroid sulfate transport processes in the human mammary gland. The Journal of clinical endocrinology and metabolism., 88(8), 3902–3912.PubMed

54.

Stute, P., Reichenbach, A., Szuwart, T., Kiesel, L., & Gotte, M. (2012). Impact of testosterone on the expression of organic anion transporting polypeptides (OATP-1A2, OATP-2B1, OATP-3A1) in malignant and non-malignant human breast cells in vitro. Maturitas., 71(4), 376–384.

55.

Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2006). Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug metabolism and disposition: the biological fate of chemicals., 34(7), 1229–1236.

56.

Nozawa, T., Suzuki, M., Takahashi, K., Yabuuchi, H., Maeda, T., Tsuji, A., & Tamai, I. (2004). Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. The Journal of pharmacology and experimental therapeutics., 311(3), 1032–1037.PubMed

57.

Tamai, I., J-i, N., Uchino, H., Sai, Y., Oku, A., Shimane, M., et al. (2000). Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochemical and biophysical research communications., 273(1), 251–260.PubMed

58.

Huber, R. D., Gao, B., Sidler Pfandler, M. A., Zhang-Fu, W., Leuthold, S., Hagenbuch, B., et al. (2007). Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. American journal of physiology Cell physiology., 292(2), C795–C806.PubMed

59.

Nozawa, T., Suzuki, M., Yabuuchi, H., Irokawa, M., Tsuji, A., & Tamai, I. (2005). Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. Pharmaceutical Research, 22(10), 1634–1641.PubMed

60.

Okabe, M., Szakács, G., Reimers, M. A., Suzuki, T., Hall, M. D., Abe, T., et al. (2008). Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Molecular cancer therapeutics., 7(9), 3081–3091.PubMedPubMedCentral

61.

Kuei-Ling, K. (2012). Localization and functional characterization of the rat Oatp4c1 transporter in an in vitro cell system and rat tissues [doctor of philosophy (PhD)]. UKnowledge: University of Kentucky.

62.

Olszewski-Hamilton, U., Svoboda, M., Thalhammer, T., Buxhofer-Ausch, V., Geissler, K., & Hamilton, G. (2011). Organic anion transporting polypeptide 5A1 (OATP5A1) in small cell lung Cancer (SCLC) cells: Possible involvement in chemoresistance to satraplatin. Biomarkers in cancer., 3, 31–40.PubMedPubMedCentral

63.

Lee, S. Y., Williamson, B., Caballero, O. L., Chen, Y. T., Scanlan, M. J., Ritter, G., et al. (2004). Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer. Cancer immunity., 4, 13.PubMed

64.

Oba-Shinjo, S. M., Caballero, O. L., Jungbluth, A. A., Rosemberg, S., Old, L. J., Simpson, A. J. G., et al. (2008). Cancer-testis (CT) antigen expression in medulloblastoma. Cancer immunity, 8, 7.PubMedPubMedCentral

65.

Zhang, L., Dresser, M. J., Gray, A. T., Yost, S. C., Terashita, S., & Giacomini, K. M. (1997). Cloning and functional expression of a human liver organic cation transporter. Molecular Pharmacology, 51(6), 913–921.PubMed

66.

Nies, A. T., Koepsell, H., Winter, S., Burk, O., Klein, K., Kerb, R., Zanger, U. M., Keppler, D., Schwab, M., & Schaeffeler, E. (2009). Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology., 50(4), 1227–1240.PubMed

67.

Nies, A. T., Koepsell, H., Damme, K., & Schwab, M. (2011). Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handbook of experimental pharmacology., 201, 105–167.

68.

Gupta, S., Wulf, G., Henjakovic, M., Koepsell, H., Burckhardt, G., & Hagos, Y. (2012). Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel. The Journal of pharmacology and experimental therapeutics., 341(1), 16–23.PubMed

69.

Thomas, J., Wang, L., Clark, R. E., & Pirmohamed, M. (2004). Active transport of imatinib into and out of cells: Implications for drug resistance. Blood., 104(12), 3739–3745.PubMed

70.

Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., Lippard, S. J., & Giacomini, K. M. (2006). Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Research., 66(17), 8847–8857.PubMedPubMedCentral

71.

Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., & Sparreboom, A. (2009). Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clinical pharmacology and therapeutics., 86(4), 396–402.PubMedPubMedCentral

72.

Hayer-Zillgen, M., Brüss, M., & Bönisch, H. (2002). Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. British journal of pharmacology., 136(6), 829–836.PubMedPubMedCentral

73.

Burger, H., Zoumaro-Djayoon, A., Boersma, A. W. M., Helleman, J., Berns, E. M. J. J., Mathijssen, R. H. J., Loos, W. J., & Wiemer, E. A. C. (2010). Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). British journal of pharmacology., 159(4), 898–908.PubMedPubMedCentral

74.

Wu, X., Huang, W., Ganapathy, M. E., Wang, H., Kekuda, R., Conway, S. J., Leibach, F. H., & Ganapathy, V. (2000). Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. American journal of physiology Renal physiology., 279(3), F449–F458.PubMed

75.

Heise, M., Lautem, A., Knapstein, J., Schattenberg, J. M., Hoppe-Lotichius, M., Foltys, D., Weiler, N., Zimmermann, A., Schad, A., Gründemann, D., Otto, G., Galle, P. R., Schuchmann, M., & Zimmermann, T. (2012). Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer, 12(1), 109.PubMedPubMedCentral

76.

Yokoo, S., Masuda, S., Yonezawa, A., Terada, T., Katsura, T., & Inui, K. (2008). Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug metabolism and disposition: the biological fate of chemicals., 36(11), 2299–2306.

77.

Shnitsar, V., Eckardt, R., Gupta, S., Grottker, J., Muller, G. A., Koepsell, H., et al. (2009). Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Research, 69(4), 1494–1501.PubMed

78.

Alcorn, J., Lu, X., Moscow, J. A., & McNamara, P. J. (2002). Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. Journal of Pharmacology and Experimental Therapeutics., 303(2), 487–496.PubMed

79.

Cai, H., Zhang, Y., Han, T., Everett, R. S., & Thakker, D. R. (2016). Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells. International journal of cancer., 138(9), 2281–2292.PubMed

80.

Tamai, I., Yabuuchi, H., Nezu, J., Sai, Y., Oku, A., Shimane, M., & Tsuji, A. (1997). Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS letters., 419(1), 107–111.PubMed

81.

Jong, N. N., & McKeage, M. J. (2014). Emerging roles of metal solute carriers in cancer mechanisms and treatment. Biopharmaceutics & Drug Disposition., 35(8), 450–462.

82.

Tamai, I., Ohashi, R., Nezu, J., Yabuuchi, H., Oku, A., Shimane, M., Sai, Y., & Tsuji, A. (1998). Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. The Journal of biological chemistry., 273(32), 20378–20382.PubMed

83.

Scalise, M., Galluccio, M., Accardi, R., Cornet, I., Tommasino, M., & Indiveri, C. (2012). Human OCTN2 (SLC22A5) is down-regulated in virus- and nonvirus-mediated cancer. Cell biochemistry and function., 30(5), 419–425.PubMed

84.

Warburg, O., Wind, F., & Negelein, E. (1927). The metabolism of tumors in the body. The Journal of general physiology., 8(6), 519–530.PubMedPubMedCentral

85.

Hu, S., Franke, R. M., Filipski, K. K., Hu, C., Orwick, S. J., de Bruijn, E. A., Burger, H., Baker, S. D., & Sparreboom, A. (2008). Interaction of imatinib with human organic ion carriers. Clinical cancer research : an official journal of the American Association for Cancer Research., 14(10), 3141–3148.

86.

Jong, N. N., Nakanishi, T., Liu, J. J., Tamai, I., & McKeage, M. J. (2011). Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons. The Journal of pharmacology and experimental therapeutics., 338(2), 537–547.PubMed

87.

Ling, B., & Alcorn, J. (2008). Acute administration of cefepime lowers L-carnitine concentrations in early lactation stage rat milk. The Journal of nutrition., 138(7), 1317–1322.PubMed

88.

Wang, C., Uray, I. P., Mazumdar, A., Mayer, J. A., & Brown, P. H. (2012). SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE). Breast Cancer Research and Treatment, 134(1), 101–115.PubMedPubMedCentral

89.

Koepsell, H., & Endou, H. (2004). The SLC22 drug transporter family. Pflügers Archiv, 447(5), 666–676.PubMed

90.

Gong, S., Lu, X., Xu, Y., Swiderski, C. F., Jordan, C. T., & Moscow, J. A. (2002). Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Experimental Hematology., 30(10), 1162–1169.PubMed

91.

Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T, Mizoi T, Shiiba K, Takanaga H, Terasaki T, Matsuno S, Sasaki I, Ito S, Abe T Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochemical and biophysical research communications. 2005;333(3):754–762.

92.

Aouida, M., Poulin, R., & Ramotar, D. (2010). The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. The Journal of biological chemistry., 285(9), 6275–6284.PubMed

93.

Nishino, S., Itoh, A., Matsuoka, H., Maeda, K., & Kamoshida, S. (2013). Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: Significance as a predictor of response to oral uracil/ftorafur plus leucovorin chemotherapy. Molecular and clinical oncology., 1(4), 661–667.PubMedPubMedCentral

94.

Sweet, D. H. (2005). Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicology and Applied Pharmacology., 204(3), 198–215.PubMed

95.

Enomoto, A., & Endou, H. (2005). Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clinical and Experimental Nephrology., 9(3), 195–205.PubMed

96.

Enomoto, A., Kimura, H., Chairoungdua, A., Shigeta, Y., Jutabha, P., Ho Cha, S., Hosoyamada, M., Takeda, M., Sekine, T., Igarashi, T., Matsuo, H., Kikuchi, Y., Oda, T., Ichida, K., Hosoya, T., Shimokata, K., Niwa, T., Kanai, Y., & Endou, H. (2002). Molecular identification of a renal urate–anion exchanger that regulates blood urate levels. Nature., 417(6887), 447–452.PubMed

97.

Monte, J. C., Nagle, M. A., Eraly, S. A., & Nigam, S. K. (2004). Identification of a novel murine organic anion transporter family member, OAT6, expressed in olfactory mucosa. Biochemical and biophysical research communications., 323(2), 429–436.PubMed

98.

Wu, W., Bush, K. T., Liu, H. C., Zhu, C., Abagyan, R., & Nigam, S. K. (2015). Shared ligands between organic anion transporters (OAT1 and OAT6) and odorant receptors. Drug metabolism and disposition: the biological fate of chemicals., 43(12), 1855–1863.

99.

Schnabolk, G. W., Youngblood, G. L., & Sweet, D. H. (2006). Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20). American journal of physiology Renal physiology., 291(2), F314–FF21.PubMedPubMedCentral

100.

Zimmerman, E. I., Gibson, A. A., Hu, S., Vasilyeva, A., Orwick, S. J., Du, G., et al. (2016). Multikinase inhibitors induce cutaneous toxicity through OAT6-mediated uptake and MAP3K7-driven cell death. Cancer Research., 76(1), 117–126.PubMed

101.

Sauter, E. R. (2017). Reliable biomarkers to identify new and recurrent cancer. European journal of breast health., 13(4), 162–167.PubMedPubMedCentral

102.

Karakus E, Zahner D, Grosser G, Leidolf R, Gundogdu C, Sánchez-Guijo A, et al. Estrone-3-sulfate stimulates the proliferation of T47D breast cancer cells stably transfected with the sodium-dependent organic anion transporter SOAT (SLC10A6). Frontiers in pharmacology. 2018;9:941-.

103.

Suzuki, T., Miki, Y., Nakamura, Y., Moriya, T., Ito, K., Ohuchi, N., & Sasano, H. (2005). Sex steroid-producing enzymes in human breast cancer. Endocrine-related cancer., 12(4), 701–720.PubMed

104.

Zhang, H., Rakha, E. A., Ball, G. R., Spiteri, I., Aleskandarany, M., Paish, E. C., Powe, D. G., Macmillan, R. D., Caldas, C., Ellis, I. O., & Green, A. R. (2010). The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Research and Treatment, 121(1), 41–51.PubMed

105.

106.

Justenhoven, C., Schaeffeler, E., Winter, S., Baisch, C., Hamann, U., Harth, V., Rabstein, S., Spickenheuer, A., Pesch, B., Brüning, T., Ko, Y. D., Schwab, M., & Brauch, H. (2011). Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk. Breast Cancer Research and Treatment, 125(2), 563–569.PubMed

107.

Zhang, X., Pu, Z., Ge, J., Shen, J., Yuan, X., & Xie, H. (2015). Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy. Medical science monitor : international medical journal of experimental and clinical research., 21, 563–569.

108.

Hashimoto, Y., Tatsumi, S., Takeda, R., Naka, A., Ogane, N., Kameda, Y., Kawachi, K., Shimizu, S., Sakai, M., & Kamoshida, S. (2014). Expression of organic anion-transporting polypeptide 1A2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Research and Treatment, 145(1), 101–111.PubMed

109.

Burckhardt, G. (2012). Drug transport by organic anion transporters (OATs). Pharmacology & Therapeutics., 136(1), 106–130.

110.

Brenner S, Klameth L, Riha J, Schölm M, Hamilton G, Bajna E, et al. (2015) Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy. Cancer Letters. 356(2, Part B):517–24.

Title: Solute transporters and malignancy: establishing the role of uptake transporters in breast cancer and breast cancer metastasis
Authors: Rachel Sutherland
Annette Meeson
Simon Lowes
Publication date: 01-09-2020
Publisher: Springer US
Keywords: Metastasis
Breast Cancer
Breast Cancer
Estrogens
Published in: Cancer and Metastasis Reviews / Issue 3/2020
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-020-09879-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

KISS1 in metastatic cancer research and treatment: potential and paradoxes

Epigenetic dynamics in cancer stem cell dormancy

Brain tumor vessels—a barrier for drug delivery

Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases

Multiple roles of HOX proteins in Metastasis: Let me count the ways

Lung cancer identification: a review on detection and classification

Keynote webinar | Spotlight on antibody–drug conjugates in cancer